• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Novartis

Novartis

Novartis AG ADR NVS

Last Price$74.12Day Change (%)-0.28%
Open Price$74.18Day Change ($)-0.21
Day Range73.78–74.3552-Week Range69.90–106.84

As of Thu 5/5/2016 5:01:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Global Hypertension Drugs Market 2016-2020 - Key Vendors are Actelion, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo Company, Novartis AG & Sanofi SA - Research and Markets

    Global Hypertension Drugs Market 2016-2020 - Key Vendors are Actelion, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo Company, Novartis AG & Sanofi SA - Research and Markets

  2. Open-Angle Glaucoma Global Clinical Trials Review 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Novartis , Allergan, Pfizer - Research and Markets

    Open-Angle Glaucoma Global Clinical Trials Review 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Novartis , Allergan, Pfizer - Research and Markets

  3. Retinal Vein Occlusion Global Clinical Trials Review 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Bayer, Pfizer, Novartis - Research and Markets

    Retinal Vein Occlusion Global Clinical Trials Review 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Bayer, Pfizer, Novartis - Research and Markets

  4. Upsized IPO of Biotech Company Intellia Prices at Top of Range

    Upsized IPO of Biotech Company Intellia Prices at Top of Range

  5. Ocular Hypertension Global Clinical Trials Review 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Santen Pharma, Aerie Pharma, Valeant Pharma - Research and Markets

    Ocular Hypertension Global Clinical Trials Review 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Santen Pharma, Aerie Pharma, Valeant Pharma - Research and Markets

  6. Chronic Urticaria Or Hives Global Clinical Trials Review, H1, 2016 - Research and Markets

    Chronic Urticaria Or Hives Global Clinical Trials Review, H1, 2016 - Research and Markets

  7. Novartis Feels the Effect Of Drop in Gleevec Sales -- WSJ

    Novartis Feels the Effect Of Drop in Gleevec Sales -- WSJ

  8. Novartis Earnings Fall on Slide in Cancer-Drug Sales --Update

    Novartis Earnings Fall on Slide in Cancer-Drug Sales --Update

  9. Novartis Earnings Fall on Slide in Cancer-Drug Sales

    Novartis Earnings Fall on Slide in Cancer-Drug Sales

  10. Novartis Earnings Fall on Slide in Cancer-Drug Sales

    Novartis Earnings Fall on Slide in Cancer-Drug Sales

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.